| Modality | Agent / program | Mechanism | Route | Key trial(s) | Phase / status | Key endpoints | Published results / evidence | Notes |
|---|---|---|---|---|---|---|---|---|
| Supportive care | Multidisciplinary symptomatic management | Seizure control, nutrition/swallow support, PT/OT/ST, orthopedic and cardiac monitoring, respiratory care | Standard clinical care | Natural-history studies used as comparator rather than interventional trial | Standard of care; no disease-modifying approval | Function, safety, quality of life, complication prevention | 10-year prospective type II cohort documented common use of antiseizure therapy, swallow studies, mobility assessment, and multisystem monitoring; no approved disease-modifying therapy as of 2024 (2024, DOI:10.1016/j.gim.2024.101144; 2021, DOI:10.2147/TACG.S206076) (pqac-00000015, pqac-00000013, pqac-00000005) | Remains the real-world baseline for type II GM1; important for tertiary prevention and trial contextualization |
| Substrate reduction therapy (SRT) | Miglustat | Inhibits glycosphingolipid synthesis to reduce upstream substrate load | Oral | Historical case series/small studies; not a current pivotal GM1 type II registration trial in retrieved context | Off-label / exploratory; mixed evidence | Neurologic function, symptom stabilization | Review summarizing small Italian experience reported gradual neurologic improvements in very small cohorts; separate infantile gangliosidoses U.S. miglustat study was terminated (2024, DOI:10.3389/fnins.2024.1392683) (pqac-00000018, pqac-00000032, pqac-00000033) | Evidence base is weak and heterogeneous; not established as standard disease-modifying therapy for type II GM1 |
| Substrate reduction therapy (SRT) | Venglustat | Brain-penetrant glucosylceramide synthase inhibitor intended to reduce glycosphingolipid biosynthesis | Oral | NCT04221451 | Phase 3; TERMINATED | Efficacy, pharmacodynamics, PK, safety | Trial record retrieved as a multinational randomized placebo-controlled study; review literature notes venglustat as an investigational small molecule for gangliosidoses/related disorders, but no GM1 type II efficacy results were available in retrieved 2023-2024 sources (ClinicalTrials.gov; 2025 biomarker review mentions investigational role) (pqac-00000017, pqac-00000000) | Important to mention because natural-history paper cites ongoing small-molecule substrate inhibitor development, but retrieved registry title is late-onset GM2-focused and status is terminated; relevance to GM1 type II appears indirect/in basket-program context rather than proven benefit |
| Gene therapy | Intravenous AAV9-GLB1 (NHGRI/Sio program; often described as AAV9/GLB1) | Gene replacement delivering human GLB1 to increase lysosomal β-galactosidase and reduce GM1 storage | Single IV infusion | NCT03952637 | Phase 1/2; RECRUITING | Primary: safety; secondary/exploratory: biomarkers, neurologic development, motor function, brain volume/myelination, immune tolerance | Trial design published in registry; review notes dosing cohorts up to 1.5E13, 4.5E13, 7.5E13 vg/kg for type II and 3-year follow-up (2024 review). Early clinical results became available later: first 9 type II participants showed increased CSF β-gal, decreased CSF GM1, imaging improvement signals, and relative stabilization in some Vineland domains, with one vector-attributed SAE and transient transaminase elevations (2025 preprint, DOI:10.1101/2025.07.28.25332074) (pqac-00000022, pqac-00000017, pqac-00000019) | Most directly relevant current systemic gene-therapy program for GM1 type II; 2023-2024 context supports active development though peer-reviewed efficacy data were not yet mature in 2024 |
| Gene therapy | PBGM01 (AAVhu68-GLB1; Imagine-1) | CNS-directed GLB1 gene replacement using AAVhu68 | Single injection into cisterna magna | NCT04713475 | Phase 1/2; ACTIVE_NOT_RECRUITING | Primary: safety / treatment-related AEs/SAEs and developmental milestone change; secondary: Vineland-II, β-gal activity, GM1 substrate levels, NfL, MRI, QoL, ventilator-free survival | Registry details include dose-escalation and expansion cohorts for Type 1 and Type 2a patients; 2-year efficacy assessment with 3-year safety extension. Reviews in 2023-2024 identify PBGM01 as one of the leading active GM1 gene-therapy programs, but no peer-reviewed efficacy data were available in the retrieved 2024 literature (ClinicalTrials.gov; 2024 review DOI:10.3389/fnins.2024.1392683) (pqac-00000023, pqac-00000018, pqac-00000021) | Key CNS-targeted alternative to IV AAV9; specifically includes late-onset infantile/type 2a patients |
| Gene therapy | LYS-GM101 (AAVrh10-GLB1; Lysogene) | CNS-directed GLB1 gene replacement | Intracisternal / CNS-directed administration | NCT04273269 | Phase 1/2; TERMINATED | Safety, dose finding, feasibility | 2023 gene-therapy review lists this as one of three clinical AAV programs entering trials; no positive clinical efficacy data retrieved, and the registry status is terminated (pqac-00000020, pqac-00000021) | Relevant as part of the competitive clinical landscape, but not a current active front-runner based on retrieved status |
| Biomarker-enabled monitoring | H3N2b pentasaccharide biomarker | Natural β-gal substrate glycan used as pharmacodynamic biomarker for treatment response | Measured in urine, plasma/serum, CSF | Embedded in gene-therapy translational studies; used alongside AAV programs | Preclinical-to-clinical translational biomarker; not a therapy itself | Reduction in H3N2b as evidence of biochemical response; assay development and validation | 2023 eBioMedicine study showed H3N2b was >18-fold elevated in patient plasma/CSF/urine, negatively correlated with β-gal activity, and fell after AAV gene therapy in cats and in a treated patient; proposed as a non-invasive pharmacodynamic biomarker (2023, DOI:10.1016/j.ebiom.2023.104627) (pqac-00000025, pqac-00000026, pqac-00000024) | Especially important for type II trials because slow disease progression makes conventional clinical endpoints difficult; useful adjunct to CSF GM1, β-gal, MRI/MRS |
| Experimental / preclinical | Pharmacological chaperones (e.g., iminosugar compound 12) | Stabilize residual mutant β-galactosidase to enhance lysosomal trafficking/activity | Oral/small-molecule concept; preclinical | No GM1 type II clinical trial in retrieved context | Preclinical | Enzyme activity rescue in variant-specific cells | 2022 medicinal chemistry study reported ~40% β-gal activity enhancement in patient leukocytes with p.Ile51Asn/p.Arg201His using a candidate chaperone (2022, DOI:10.3390/molecules27134008) (pqac-00000053) | Precision-medicine potential for residual-activity type II genotypes, but far from clinical implementation |
| Experimental / preclinical | Base editing / gene editing of GLB1 | Correct pathogenic GLB1 SNVs in patient-derived cells | Ex vivo / in vitro | No registered human interventional GM1 type II gene-editing trial retrieved | Preclinical | Editing efficiency, β-gal restoration, off-target profile | 2023 CRISPR Journal study reported that 41% of pathogenic GLB1 SNVs may be targetable by adenine base editors and demonstrated restoration of therapeutic β-gal levels in patient fibroblasts (2023, DOI:10.1089/crispr.2022.0045) (pqac-00000020) | Important emerging direction but not yet clinically implemented for type II GM1 |
| Experimental / future | Prenatal AAV9-GLB1 gene transfer | Very-early gene replacement before advanced neurodegeneration | Prenatal IV fetal administration | NCT07479953 | Phase 1; NOT_YET_RECRUITING | Feasibility, safety, prenatal delivery outcomes | Trial registry indicates fetal enrollment at 28-35+6 weeks with genetically confirmed type I or II GM1 and extensive prenatal genetic confirmation requirements (ClinicalTrials.gov) (pqac-00000051) | Highly experimental; conceptually important because earlier intervention is widely viewed as critical in neuronopathic lysosomal disease |


*Table: This table summarizes the main current and emerging therapeutic approaches and clinical trials relevant to GM1 gangliosidosis type II, with emphasis on 2023-2024 developments. It highlights active gene-therapy programs, SRT efforts, and the H3N2b biomarker that is increasingly important for monitoring treatment response in slow-progressing disease.*